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Multi-lectin Affinity 
Chromatography and Quantitative 
Proteomic Analysis Reveal 
Differential Glycoform Levels 
between Prostate Cancer and 
Benign Prostatic Hyperplasia Sera
Sarah M. Totten1, Ravali Adusumilli1, Majlinda Kullolli1, Cheylene Tanimoto  1, James D. Brooks2, 
Parag Mallick1 & Sharon J. Pitteri  1
Currently prostate-specific antigen is used for prostate cancer (PCa) screening, however it lacks 
the necessary specificity for differentiating PCa from other diseases of the prostate such as benign 
prostatic hyperplasia (BPH), presenting a clinical need to distinguish these cases at the molecular level. 
Protein glycosylation plays an important role in a number of cellular processes involved in neoplastic 
progression and is aberrant in PCa. In this study, we systematically interrogate the alterations in 
the circulating levels of hundreds of serum proteins and their glycoforms in PCa and BPH samples 
using multi-lectin affinity chromatography and quantitative mass spectrometry-based proteomics. 
Specific lectins (AAL, PHA-L and PHA-E) were used to target and chromatographically separate core-
fucosylated and highly-branched protein glycoforms for analysis, as differential expression of these 
glycan types have been previously associated with PCa. Global levels of CD5L, CFP, C8A, BST1, and C7 
were significantly increased in the PCa samples. Notable glycoform-specific alterations between BPH 
and PCa were identified among proteins CD163, C4A, and ATRN in the PHA-L/E fraction and among 
C4BPB and AZGP1 glycoforms in the AAL fraction. Despite these modest differences, substantial 
similarities in glycoproteomic profiles were observed between PCa and BPH sera.
Prostate cancer (PCa) is one of the most common cancers among men in the U.S., with a projected 161,360 new 
cases in 2017 and an estimated 26,730 prostate cancer deaths1. For nearly three decades, prostate-specific antigen 
(PSA) has been used for prostate cancer screening, resulting in a significant increase in the number of detected 
cases of prostate cancer, with a shift toward detecting the cancer at earlier stages2,3. The beneficial effects of PSA 
screening are still debated, as conflicting evidence has been presented regarding whether or not it reduces prostate 
cancer mortality rates3–7. Circulating levels of PSA are also affected by other conditions of the prostate, including 
certain infections and inflammation, such as prostatitis, and benign enlargement of the prostate (benign prostatic 
hyperplasia, or BPH)8. Due to this lack of specificity for prostate cancer, the diagnostic capability of PSA suffers 
from a high number of false positives, resulting in unnecessary biopsies and overdiagnosis. Therefore there is a 
clinical need for a biomarker with greater specificity for prostate cancer that can distinguish between patients with 
benign disease from those at higher risk for prostate cancer, allowing patients to receive appropriate treatment 
and thus reducing the number of unnecessary biopsies, invasive surgeries, and the associated side effects.
The blood contains thousands of circulating proteins that are reflective of physiological and pathological states 
within the body, providing a rich source of potential biomarkers that can be easily sampled through less inva-
sive means. However, performing in-depth plasma or serum proteomics is analytically challenging due to the 
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complexity of the protein mixture and the large dynamic range of protein concentrations in the blood, which 
spans more than ten orders of magnitude9. This challenge has been met with a number of chromatography and 
mass spectrometry-based approaches designed to systematically achieve greater coverage deeper into the plasma/
serum proteome, ranging from the selection of specific subsets of proteins through affinity chromatography, 
to extensive pre-fractionation at the protein and peptide level10. The depth of proteomic analysis has also been 
enhanced by technological improvements in high-performance mass spectrometers with greater scan speeds, 
resolving power, and sensitivity. Furthermore, it is estimated that over 50% of the human proteome is glyco-
sylated11. Glycosylation is a common yet highly complex post-translational modification recognized to play an 
important role in a variety of biological processes, such as cell-cell communication, host-pathogen interactions, 
and immune response12–14. Glycoproteins can have multiple sites of glycosylation with varying degrees of occu-
pancy. Additionally, a variety of different glycans can occupy a given glycosylation site, giving rise to the com-
plex microheterogeneity that notoriously complicates the characterization and analysis of protein glycosylation. 
Changes in glycosylation have been correlated to disease status in a variety of cancers, including prostate cancer, 
and exploiting these aberrancies has shown promise for use as effective biomarkers13,15–18. The bulk of the research 
on glycosylation changes in prostate cancer has focused on characterizing the various glycoforms of PSA to 
improve its clinical utility19–23. These studies find that core-fucosylation and the sialic acid linkage of PSA glyco-
forms play a key role in differentiating non-PCa patients and those with BPH from low- and high-risk PCa cases. 
A number of glycomic and glycoproteomic studies have also looked beyond PSA for prostate cancer-specific 
glycosylation changes in a variety of clinical samples, including urine, seminal fluid, blood plasma/serum and 
tissue24. In a review by Drake et al., it was reported that an increase in the expression of N-acetylglucosaminyl 
transferase V in prostate tumors leads to a subsequent increase in β1–6 branching, forming larger tri- and tetraan-
tennary N-linked structures in prostate tissue24. Additionally, a recent review describing the mechanisms and 
clinical implications of altered glycosylation in cancer reports that an increases in glycan branching, as well as 
increased fucosylation and sialylation, are the most widely occurring cancer-associated alterations in protein gly-
cosylation13. Although progress has been made in realizing the importance of glycosylation in the development 
and progression of cancer, it still remains a significant analytical challenge to obtain detailed glycan characteri-
zation while still retaining protein- and site-specific, information in large, complex biological mixtures derived 
from clinical samples.
In this study, we perform a quantitative glycoproteomic analysis using multi-lectin affinity chromatography 
(M-LAC) to compare the circulating levels of proteins and their glycoforms from the sera of men with BPH to 
those with prostate cancer. We use a series of chromatographic separations to simultaneously decomplex the 
protein mixture and to enrich for proteins with specific types of glycosylation by using lectins with affinity for 
specific glycan motifs. Here we chose Aleuria aurantia lectin (AAL) to capture core-fucosylated proteins and 
Phaseolus vulgaris leucoagglutinin erythroagglutinin, and Phaseolus vulgaris erythroagglutinin (jointly abbrevi-
ated as PHA-L/E) to capture highly branched glycans25. These lectins were chosen to target types of glycosylation 
reported to be aberrant in prostate cancer, while simultaneously fractionating the complex mixture of proteins 
to enhance depth of analysis. Using an M-LAC approach to separate glycoforms allows for a systematic way to 
screen for changes in glycosylation in a complex mixture while retaining protein-specific information. We iden-
tify differences at the global protein level as well as among specific glycoforms of quantitated proteins that could 
be used to aid in differentiating BPH from PCa cases.
Methods
Methods. Serum Sample Collection from Benign Prostatic Hyperplasia and Prostate Cancer Patients. De-identified 
serum samples used in this study were taken from an existing serum bank collected on patients immediately prior 
to surgery for prostate cancer, or from men with elevated serum PSA levels, known BPH, and two or more previous 
negative prostate biopsies. Following informed consent, all blood samples were collected in red top tubes, allowed to 
clot, and centrifuged. Serum was then aliquoted (500 μL) into tubes and frozen at −80 °C to limit effects of freeze/thaw 
cycles. Samples were retrieved and analyzed. All ten PCa samples were from men in whom the cancer volume was 1 cc 
or greater and showed pathological Gleason scores of 4 + 3 = 7 (Table 1). Use of the existing serum resource has been 
reviewed and certified by the Stanford University Institutional Review Board (IRB). The approved IRB protocol for 
blood collection allows for correlation of clinical information, including disease status and follow-up, with molecular 
measurements in the blood, including protein analysis. The patients have provided informed consent allowing for use of 
their tissues/blood specimens. Samples collected prior to 1999 are considered existing samples in an established clinical 
and tissue database, and can be used under an IRB approved Waiver.
Immunodepletion of Abundant Proteins. Pooled normal human male EDTA plasma was purchased from 
Innovative Research and used as a reference sample pool. 200 µL of each clinical serum sample (17 in total) and 
17–200 µL aliquots of the reference pool were immunodepleted using CaptureSelectTM HumanPlasma 14 affin-
ity resin for the removal of abundant proteins (albumin, IgG, IgM, IgA, IgE, IgD, free light chains, transferrin, 
fibrinogen, α-1-antitrypsin, apolipoprotein A1, α-1-2-macroglobulin, α-1-acid-glycoprotein, and haptoglobin) 
as previously described26. The flow-through fractions from the CaptureSelect column containing the unbound 
proteins were desalted and concentrated using Amicon Ultra 15 mL 3 K NMWL centrifugal filters (Millipore). 
An aliquot of 10 µL from each concentrated sample was set aside for a Bradford assay to determine total protein 
concentration, and the remainder of the sample was diluted 1:10 in protein denaturation buffer (8 M urea, 50 mM 
Tris-HCl, 0.05% octyl β-D-glucopyranoside, pH 7.5, prepared in 100 mM ammonium bicarbonate).
Reduction, Alkylation, and Isotopic Labeling. Protein disulfide bonds were reduced using dithiothreitol (DTT) 
at a final concentration of 5.5 mM for two hours at room temperature. Cysteine residues were alkylated using 
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acrylamide for one hour at room temperature in the dark. For relative quantitation, all clinical BPH and PCa 
samples were alkylated with 1,2,3-13C3 (heavy) acrylamide in a 7.4 mg per mg of protein ratio, and all reference 
samples were alkylated with 1,2,3-12C3 (light) acrylamide in a 7.1 mg per mg of protein, as described in Faca 
et al.27. After alkylation, each clinical sample was then combined with a reference sample, making 7 BPH/
Reference pairs and 10 PCa/Reference pairs. Each pair was concentrated and buffer exchanged into 1 mL of 
1 × PBS for subsequent lectin chromatography.
Multi-Lectin Affinity Chromatography. Multi-lectin affinity chromatography (M-LAC) was used to sepa-
rate proteins by specific glycoforms. The following M-LAC experiments were modified for use on this specific 
application from previously described methodologies employing immunodepletion and M-LAC to investigate 
glycoproteomic changes in human plasma and serum28–32. Aleuria aurantia lectin (AAL), Phaseolus vulgaris leu-
coagglutinin, and Phaseolus vulgaris erythroagglutinin (PHA-L/E) were used to capture core fucosylated pro-
tein glycoforms, and glycoforms carrying highly branched complex type glycans, respectively. Agarose-bound 
AAL and PHA-L/E lectins were purchased from Vector Laboratories (Burlingame, CA) and gravity packed in 
house, as previously described25. All chromatography was performed on an Agilent 1260 Bio-Inert HPLC system, 
equipped with a quaternary pump, a manual injector, UV multiple wavelength detector, and an analytical-scale 
fraction collector. Reduced and alkylated protein was loaded onto the M-LAC column for fractionation. First 
the flow-through fraction was collected, containing the non- or otherwise-glycosylated proteins making up 
the unbound (UNB) fraction. Bound glycoproteins were eluted in series using competitive saccharide binding 
and low pH elution buffers. Core-fucosylated glycoforms bound to AAL were eluted with 200 mM L-fucose 
ACROS Organics). Lastly, glycoforms bound to PHA-L/E were eluted with 100 mM acetic acid, pH 3.8. Each of 
the three M-LAC fractions (henceforth abbreviated as UNB, AAL, and PHA) were concentrated to 250 µL using 
3 K NMWL Amicon centrifugal filters.
Reversed-Phase Chromatography. Reversed-phase (RP) fractionation was performed on a 100 mm × 2.1 mm 
ID stainless steel column packed with POROS®R2 (Applied Biosystems), with a 2,000 Å particle size, poly 
styrene-divinylbenzene stationary phase. Each M-LAC fraction was further separated into 13 RP fractions using 
an increasing gradient of organic mobile phase as follows: 0–5 minutes at 100% buffer A (0.1% trifluoroacetic 
acid in water); 5–38 minutes, ramp to 90% buffer B (0.1% trifluoroacetic acid in acetonitrile); 38–40 minutes 
hold at 90% buffer B; 40–50 minutes hold at 95% buffer A for re-equilibration. In total, 39 fractions (13 RP frac-
tions x 3 M-LAC fractions) were collected per patient sample. All fractions were frozen at −80 °C overnight and 
lyophilized. RP fractions were reconstituted in 50 µL of 50 mM ammonium bicarbonate in 4% acetonitrile and 
subsequently digested with 0.5 µg of trypsin at 37 °C for 18 hours.
LC – Tandem Mass Spectrometry Analysis. Tryptic peptides were analyzed by LC-MS/MS on an Ultimate 3000 
RSLCnano system (Dionex) coupled to an Orbitrap Elite mass spectrometer (Thermo Fischer Scientific) with a 
nanospray ion source. Fifteen µL of sample (approximately 5–10 µg of peptides) was loaded onto a C18 trap col-
umn for brief desalting and concentration, then separated on a 25 cm C18 analytical column (Picofrit 75 µm ID, 
New Objective, packed with MagicC18 AQ resin) over a 140 minute, multi-step gradient of increasing organic 
phase. Each MS/MS experiment consisted of an initial MS1 scan over a mass range of 400–1800 m/z, followed 
Sample Type & Number Age PSA (ng/mL) Percent G4/5* Total Cancer Volume (cc)
PCa_1 56 10.20 70 4.37
PCa_2 66 3.92 90 8.55
PCa_3 50 15.48 80 9.00
PCa_4 58 6.36 60 9.03
PCa_5 60 21.30 90 4.93
PCa_6 70 3.27 70 6.00
PCa_7 46 30.13 90 1.00
PCa_8 68 16.11 95 29.39
PCa_9 64 13.40 60 7.20
PCa_10 56 8.71 50 4.56
BPH_1 62 3.14
N/A
BPH_2 73 4.20
BPH_3 69 11.16
BPH_4 71 13.80
BPH_5 56 7.67
BPH_6 44 3.42
BPH_7 61 8.21
Table 1. Clinical Characteristics of PCa and BPH samples. *Percentage of Gleason Pattern 4 or 5. The 
remainder is pattern 3. All PCa samples are Gleason 4 + 3 = 7.
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by 10 subsequent data-dependent collision-induced dissociation (CID) fragmentation events of the top 10 most 
intense +2 or +3 ions from the MS1 spectrum over an acquisition time of 140 minutes.
Data Processing and Statistical Analysis. The raw files obtained from LC-MS/MS were converted to mzXML 
format using MSconvert from the ProteoWizard software33. The resulting mzXML files were used to identify 
proteins by searching against human UniProtKB database on the LabKey server using X!Tandem algorithm34–36. 
Search results from X!Tandem were then analyzed by PeptideProphet and validated using ProteinProphet37,38. 
Protein groups and peptides with a score greater than 0.9 and 0.6, respectively, were retained for protein identifi-
cation and quantitation. Heavy-to-light (H/L) ratioswere computed for cysteine-containing peptides with acryla-
mide labels using the Q3 quantitation algorithm27. The fragment ion mass accuracy was set to the default ±0.5 Da 
in X!Tandem. Only peptides with precursor fractional delta mass <20 ppm were used for quantitation. Peptide 
H/L ratios were averaged for each protein group by each M-LAC fraction resulting in three separate quantitation 
values for UNB, AAL and PHA. Additionally, global protein levels were calculated as an average of all glycoforms, 
using all quantitated peptides regardless of which M-LAC fraction the peptide was identified in. Protein groups 
were subsequently assembled by gene name into normalized gene groups. One gene name was picked to represent 
each group. H/L ratios of each group were log(2) transformed and median-centered (across all fractions per sam-
ple) for normalization. A permutation two-sample t-test (Welch’s unequal variance) was performed on the mean 
H/L ratios for genes quantified in BPH and PCa groups using perm (R package) to randomly shuffle the data and 
estimate the distribution of the test statistic39. The p-value for the observed test statistic was then determined from 
the sampling distribution. False discovery rate (FDR) was estimated from the permutation test as the number of 
false discoveries at or above a given p-value. We used an FDR bound of 1% throughout the manuscript for differ-
ential quantification. Permutation tests were only performed on proteins that were quantified in ≥3 samples in 
both the BPH and PCa groups.
Method Reproducibility. The reproducibility of the entire platform described above was accessed using three 
identical replicates of the reference plasma designed to yield a 1:1 heavy-to-light ratio by combining 1,2,3-13C3 
heavy-labeled reference plasma with 1,2,3-12C3 light-labeled reference plasma. After immunodepletion, reduction, 
and alkylation/labeling steps, each of the three replicates were separated by M-LAC, RP fractionated, digested, 
and analyazed by LC-MS/MS as described above. The identical replicates yielded acceptable reproducibility, 
and the data from these experiments is presented in the supplementary material (see Supplementary Dataset 1 
for lists of identified peptides with quantitation, and Supplementary Figures S1 and S2 for spectral count and H/L 
ratio reproducibility, respectively).
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
The overall objective of this study was to elucidate differences in the circulating levels of serum protein glyco-
forms that may have utility in distinguishing between PCa patients from those with BPH. Multi-dimensional 
chromatographic separation at the intact protein level was used to increase the depth of proteomic analysis 
given the dynamic range issues associated with blood plasma and serum. Using lectins to fractionate the pro-
tein mixture also provides the ability to separate protein glycoforms and to obtain an additional layer of infor-
mation concerning the types of glycosylation expressed on serum glycoproteins. By using lectins with affinity 
for particular glycan structures, it is possible to systematically monitor global changes to the levels of specific 
glycoforms across hundreds of serum proteins from PCa and BPH specimens. Figure 1 shows an overview of 
the analytical design of these experiments, where all cases (7 BPH samples and 10 PCa samples) were quanti-
tated relative to a pooled reference sample of male plasma that served as an internal control. Each PCa and BPH 
sample was isotopically labeled with heavy 13C-acrylamide, and combined with the reference sample (labeled 
with a light 12C-acrylamide isotope). Each sample was then loaded onto an M-LAC columncontaining AAL 
and PHA-L/E lectins. AAL preferentially binds fucose linked α1-6 to N-Acetylglucosamine (GlcNAc), and – to 
a lesser extent – fucose linked α1-3 to N-acetyllactosamine (LacNAc), and was used to enrich for primarily 
core-fucosylated N-linked glycoforms and to a lesser extent terminal fucosylated N-linked glycoforms14. PHA-L 
has affinity for tri- and tetra-antennary complex-type glycans, while PHA-E recognizes bisected di-, and triant-
ennary complex-type N-linked glycans14. These two lectins were used together to enrich for protein glycoforms 
containing highly-branched, complex-type structures. Three separate fractions were collected from the M-LAC 
column including the flow-through of unbound proteins (UNB fraction), proteins bound to AAL (AAL fraction), 
and proteins bound to PHA-L/E (PHA fraction). For each specimen, each of the three M-LAC fractions was then 
further fractionated by reversed-phase chromatography, trypsinized, and analyzed by LC-MS/MS, as described 
in detail above. For complete lists of peptide identification and quantitation per fraction, per sample, please see 
Supplementary Dataset 1. Comparisons were made between PCa and BPH groups among proteins that were 
quantitated in at least three samples in each group. For a complete list of all protein H/L values in each sample, 
please refer to Supplementary Dataset 2.
Depth of Proteomic Analysis. Due to the complexity and large dynamic range of protein concentrations 
inherent to the human serum and plasma proteome, we opted to pre-fractionate the protein mixture to increase 
lower-abundance protein identifications10. The use of high-resolution mass spectrometry also increases the number 
of identifications and the extent of protein sequence coverage. In this study, samples were extensively fractionated 
at the intact protein level and separated by glycoform. By LC-MS/MS analysis, on average, 187 proteins (5% FDR, 
collapsed by gene name, quantified in at least three samples) were quantitated in the UNB fraction, 141 in the AAL 
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fraction, and 159 in the PHA fraction among the PCa specimens. The BPH serum samples yielded 183, 183, and 
203 quantitated proteins in the UNB, AAL, and PHA fractions, respectively. These numbers of quantitated proteins 
results are typical for the chosen methodology, which involves the isotopic labeling of cysteine residues via alkylation 
with heavy and light isotopes of acrylamide, as described above. A cysteine labeling approach was utilized for effi-
cient labeling at the protein level (versus peptide level) to ensure compatibility with the intact protein fractionation 
used in our sample preparation. Quantitation is therefore limited to cysteine-containing peptides, which restricts 
the number of proteins available for quantitation. Furthermore, the reported number of proteins quantitated across 
samples is a result of restricting proteins to those present in at least three samples in both the BPH and PCa groups 
to allow for statistical analysis. Figure 2 demonstrates the range of proteins quantitated in a single representative 
sample (BPH_3, Table 1), plotting spectral counts versus cumulative number of quantitated proteins. Spectral counts 
and known proteins concentrations in blood were used to estimate the dynamic range of the fractionated protein 
mixture, which contained proteins with concentrations ranging from micrograms per milliliter (such as C3, VTN, 
and AZGP1) down to the nanogram per milliliter level (such as MMP2, ICAM1, and CEACAM1)9,40–42. A complete 
list of the number of proteins quantified for each individual sample can be found in Supplementary Dataset 3, and a 
list of identified peptide sequences can be found in Supplementary Dataset 1.
Protein Expression Relative to Reference Sample. To quantitate alterations in protein abun-
dance, cases (BPH or PCa) were isotopically labeled with heavy 1,2,3 13C-acrylamide. All cases were compared 
against a reference pool sample isotopically labeled with the light 12C-acrylamide isotope. The mass of 13C- and 
Reference 
Pool Plasma
PCa Plasma
N= 10
BPH Plasma
N= 7
(13C Acrylamide)
M-LAC M-LAC
UNB AAL PHA UNB AAL PHA
Reversed-Phase 
Chromatography
LC-MS/MS
Reversed-Phase 
Chromatography
H/L _BPH H/L _PCa
(Welch T-test)
LC-MS/MS
(13C Acrylamide)(12C Acrylamide)
H
L
H
L
Figure 1. Experimental Design and Analytical Work Flow.
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12C-acrylamide differs by 3 Daltons, inducing a shift in the mass spectrum of cysteine-containing peptides. The 
heavy-to-light (H/L) ratio is calculated based on the peak intensity of the heavy and light forms of the peptide 
integrated across the elution of the peak. An overview of protein quantitation relative to the reference sample is 
presented in Fig. 3, which features a heat map color-coded by average log2H/L values for each M-LAC fraction in 
PCa and BPH groups. The proteins are ordered along the horizontal axis from high to low global protein log2H/L 
values in the PCa group. The set of 248 proteins presented in Fig. 3 includes all quantitated proteins with an n ≥ 3 
at the global protein level (i.e. there were at least three samples containing the protein in both groups). Blank 
(white) spaces in the heat map indicate one of two instances: (1) there were not enough data points (n < 3) in the 
group to perform statistical analysis, or (2) protein glycoforms were not detected in that fraction in any sample 
(n = 0). In the former, the H/L data points that were present contributed to the global protein level.
Both PCa and BPH demonstrate deviation from the reference sample, however, the patterns in protein expres-
sion were overall quite similar between the BPH and PCa groups. At the global protein level, the most overex-
pressed proteins (with respect to the reference sample) in the PCa samples were also highly overexpressed in the 
BPH group, including SPARC, metalloproteinases MMP2 and MMP9, ADAMTS13, MENT, COMP, SNED1, 
SLPI, and PCSK9. Similarly, proteins with decreased global levels in the PCa group showed comparable decreased 
levels in the BPH group, including SERPINA4, S100A8, and PON1, among others. The most over-expressed 
protein in the dataset was MMRN1 (multimerin-1), a glycoprotein with 23 N-linked glycosylation sites that 
was exclusively detected in the AAL fraction. Global MMRN1 levels were highly elevated in both groups, with a 
six-fold increase quantitated in the PCA group and a seven-fold increase in the BPH group (PCA log2H/L = 2.59, 
BPH log2H/L = 2.91, p-value = 0.477). In general, the same trend was found among the protein levels in indi-
vidual M-LAC fractions. For most proteins, fold-changes were in concordant directions across M-LAC fractions 
and were similarly expressed with respect to the reference sample in the PCa and BPH groups. Additionally, 
protein glycoforms were typically identified in the same M-LAC fractions in the PCa and BPH groups. We did 
not observe any cases in which all of the PCa glycoforms of a given protein were found in one M-LAC fraction 
and all the BPH glycoforms of that same protein were found in another, which would have clearly indicated a 
blatant contrast in glycosylation patterns. However, some glycoform-specific alterations were observed that were 
not immediately apparent at the global protein level. For example, MINPP1 (Fig. 3) was quantitated in all three 
fractions, but demonstrated elevated levels in the UNB fraction, decreased levels among the AAL glycoforms, 
and relatively unchanged levels among the PHA glycoforms. The global protein level was slightly overexpressed 
(less than 1.5-fold), demonstrating which M-LAC fractions were driving the overall trend. This trend, however, 
was observed in both the PCa and BPH groups, rendering MINPP1 ineffective for distinguishing PCA from BPH. 
ADAMTSL4, SSC5D, VCAM1, and IGFBP7, to highlight a few, presented similar cases in which different M-LAC 
fractions showed log2H/L ratios in opposing directions – a trend that would not have been observed without 
glycosylation-based fractionation – but ultimately resulted in indistinguishable patterns between PCa and BPH 
groups.
In some cases there were insufficient data points to quantitate glycoforms of individual M-LAC fractions, 
but had an n ≥ 3 once values from all fractions were combined to determine a global protein level, as is shown in 
Fig. 3. TRIM37, JAG1, RECK, ASGR2, and SPARCL1 all demonstrated at least 1.5-fold over-expression compared 
to the reference sample at the global protein level in PCa and BPH groups. Some of the more striking differences 
were observed in TFRC and APOF, in which the BPH group demonstrated a 2-fold increase, while the PCa group 
was unchanged (TFRC) or decreased (APOF).
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Figure 2. Depth of Proteomic Analysis – the above figure plots the spectral count (per protein) against the 
cumulative number of quantitated proteins ordered from highest to lowest spectral count (by unique gene 
name). Examples of the types of proteins that were quantitated are highlighted in red for reference. Literature 
values of concentrations for these proteins were used to estimate the dynamic range of the protein mixture. 
This plot was generated from a single, representative sample with an average number of protein identifications. 
Across all M-LAC fractions, 315 proteins were quantitated in this sample.
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Differential Expression Between PCa and BPH. Among the quantitated proteins shown in Fig. 3, a per-
mutation t-test was performed to determine significant differences between the BPH and PCa log2H/L ratios for 
those with an n ≥ 3 in each group. A t-test was done at the global protein level, which was calculated as an average 
of all identified glycoforms, for which 248 comparisons were made. Comparisons were also made between each of 
the three M-LAC fraction (for proteins with n ≥ 3 within that fraction). Altogether 153 proteins were compared 
in the AAL fraction, 156 in the PHA fraction, and 168 in the UNB fraction. A complete list of PCa and BPH mean 
log2H/L values and corresponding p-values can be found in Supplementary Dataset 4. To determine the extent 
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Figure 3. Heat map color-coded by mean fold change (log2H/L) in the PCa and BPH groups with respect to the 
reference plasma. Each M-LAC fraction is represented in its own column and proteins are ordered from largest 
fold change in the PCa group at the global protein level. This list of 248 proteins includes those that had an N ≥ 3 
for quantitation per M-LAC fraction and/or at the global protein level (far right).
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of differential expression in protein levels between PCa and BPH groups, the difference in mean log2H/L was 
calculated for each protein (Δ = log2H/LPCa − log2H/LBPH) and plotted in Fig. 4. This figure illustrates a summary 
of the direction and magnitude of the difference in log2H/L values in each M-LAC fraction for proteins that had 
statistically significant differences in one, two, or all three fractions, and/or at the global protein level. Fifty-nine 
proteins had significantly different levels (p-values ≤ 0.05) at the global protein level. Additionally, 18 were sig-
nificantly different in the AAL fraction, 30 in the PHA fraction, and 37 in the unbound UNB fraction. As shown 
in Fig. 4, proteins were organized into groups according to the pattern in which the protein levels were altered. In 
some instances, proteins yielded increased or decreased levels in the PCa relative to the BPH uniformly across all 
quantitated glycoforms. Seven proteins were quantitated in all three M-LAC fractions and demonstrated differ-
ential expression irrespective of glycosylation, as shown in Group A in Fig. 4. Of these, CD5L was the only protein 
to have significantly over-expressed protein levels that were higher in the PCa than the BPH in every fraction. 
Circulating levels of F2, ITIH1, ITIH4, PPBP, APOE, and SERPINA3 were lower in PCa than in the BPH across all 
glycoforms. Similarly, proteins in Group B (Fig. 4) yielded significantly different protein levels in PCa versus BPH 
in every fraction that they were quantitated in, but were not detected and/or quantitated in all three fractions. 
Group C (Fig. 4) contains proteins in which significant differences were only determined at the global protein 
level, suggesting the trend was only statistically significant when expressed as an average of all detected glyco-
forms due to the cumulative effect of combining all the data points and increasing the statistical power. Among 
these, global levels of PTPRM, MCAM, DEFA1B, CFHR1, BST1, PF4, VTN, and C7 were significantly higher in 
the PCa group than in the BPH group, and LSAMP, TFRC, KLKB1, ABI3BP, GPX3, AHSG, GSN, B2M, FETUB, 
LRG1, and C1QC were significantly lower in the PCa than in the BPH.
Glycoform-specific changes in protein expression. In many cases, glycoform-specific alterations were observed 
in the patterns of protein expression between the PCa and BPH groups, as is depicted in Groups D, E, and F in 
Fig. 4. Proteins in Group D were quantitated in all M-LAC fractions and yielded significant differences among 
multiple glycoforms. Properdin (CFP) showed significantly elevated levels in PCa compared to BPH among 
core-fucosylated glycoforms bound to AAL and among the other-wise or non-glycosylated forms quantitated in 
the unbound fraction. Proteins AZGP1, and C4BPB also demonstrated significantly higher levels in glycoforms 
containing core-fucosylated glycans in the AAL fraction and highly-branched glycans in the PHA fraction, how-
ever was not significantly different in the unbound fraction. Notably, the comparison in AZGP1 in the unbound 
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Figure 4. Difference in mean (Δ = log2H/L_PCa − log2H/L_BPH) plotted by M-LAC fraction per protein. 
Asterisk denotes a statistically significant difference in mean (p ≤ 0.05). Proteins are grouped by expression 
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in every M-LAC fraction it was quantitated in; (C) Only significant at the global protein level; (D) Significantly 
different in multiple M-LAC fractions; (E) Significantly different in only one M-LAC fraction and at the global 
protein level; (F) Significantly different in one M-LAC fraction and not at the global protein level.
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fraction was nearly significant (p = 0.06) and demonstrated a similar trend of increased levels in PCa patients, 
suggesting that AZGP1 may be over-expressed at the protein level and not necessarily displaying differential 
glycosylation. However, proteins in Groups E and F were only significantly different in a single M-LAC fraction 
(proteins in Group E were also significant at the global protein level). For example, proteins such as APOM 
and CD163 showed significantly increased levels in the PCa group versus the BPH group only in the PHA frac-
tion, however a similar, although insignificant, trend was observed among the glycoforms in the UNB and AAL 
fractions as well. Interestingly, Group F includes 20 proteins that showed significant differences only in a single 
M-LAC fraction and were not significant at the global protein level, demonstrating the advantage of fractionat-
ing intact proteins by glycoform prior to digestion and MS analysis. Notable in this group is ATRN, which was 
significantly increased in the PHA fraction exclusively, suggesting that only the highly-branched, complex type 
glycoforms of this protein were expressed in higher concentrations in PCa patients. Additionally, several mem-
bers of the complement family yielded lower levels of core-fucosylated glycoforms in PCa patients relative to BPH 
patients, including C2, C5, and C9. It should be noted that although the difference between the PCa and BPH 
means were negative in these three proteins (as shown in Fig. 4), all the log2H/L ratios were positive compared to 
the reference sample, but just to a lesser extent in the PCa group than in the BPH group. This is most notably the 
case in the AAL fraction of C9, for which the BPH mean was 2-fold higher than the reference sample, and the PCa 
mean was only 1.11-fold higher than the reference sample (p = 0.024).
In the case of KNG1, the changes in protein level was significantly different in all M-LAC fractions, but not 
in concordant directions. KNG1 protein levels were lower in the PCa group among glycoforms in the AAL and 
PHA fractions, but were elevated in the non- or otherwise-glycosylated forms in the UNB fraction. In this case, 
the opposing trends among the M-LAC fractions resulted in a loss of significance at the global protein level. By 
fractionating by glycosylation type, we were able to find differences among certain glycoforms, even when the 
global protein level was unchanged – a trend that would have been missed in proteomic workflows that do not 
target glycoproteins specifically.
Discussion
In this study we compare alterations in protein expression in men with BPH relative to normal male plasma to the 
differential protein expression derived from prostate cancer patients. We hypothesized that differential expres-
sion would be observed among protein glycoforms in specific M-LAC fractions and that these differences may 
show potential for distinguishing BPH from PCa. We observed alterations in circulating levels of proteins both 
at the global level and among specific glycoforms captured by lectins with affinity for core-fucosylated species 
(AAL) and highly branched complex-type glycans (PHA-L/E). Quantitation relative to a pooled reference sample 
revealed substantial similarity in protein and glycoprotein expression among PCa and BPH groups, leaving only 
a small number of cancer-specific alterations. For this reason, we included proteins with a fold change of ≥1.5 
(0.585 on a log2 scale) in our analysis to improve our sensitivity for smaller, more subtle changes in protein level. 
The extent of overlap in protein expression patterns between these two groups is not entirely unexpected, as it is 
known that inflammatory and immune response proteins are detectable in the blood of cancer patients in addi-
tion to proteins derived from the tumor itself43. These results speak to the difficulty in identifying (glyco)proteins 
that can effectively distinguish PCa from BPH, which is a pitfall of the currently used clinical biomarker for pros-
tate cancer, PSA. Inflammation plays a role in the pathogenesis of both BPH and cancer43–46, and indeed a num-
ber of inflammation-associated proteins were detected and quantitated within this sample set. Predominating 
among these were several glycoproteins of the complement system. Notably, complement activators MASP2, 
or mannan-binding lectin serine protease-2, C1S, and the subsequent pro-inflammatory cleavage product C4A 
all showed elevated levels in all M-LAC fractions among both PCa and BPH patients47. Although considerably 
increased compared to the reference sample, the abundances of these proteins and their separated glycoforms 
were similarly altered in both groups and may not serve as ideal cancer-specific markers. Notably, SPARC – a 
secreted glycoprotein that plays a role in tissue remodeling through interactions with the extracellular matrix – 
was overexpressed by at least 3-fold with respect to the reference sample in both PCa and BPH across all M-LAC 
fractions. Although SPARC has been reported to be dysregulated in several different types of cancers48,49, has been 
associated with prostate cancer progression and bone metastasis50–53, and has been suggested as a possible target 
for cancer therapeutics48,54,55, the elevated global protein level of SPARC in this study was determined to be non-
specific for prostate cancer. A significant difference between PCa and BPH was observed only in the UNB frac-
tion, in which the levels of non- or otherwise-glycosylated forms of SPARC were significantly higher in the PCa 
group (PCA log2H/L = 2.58, BPH log2H/L = 1.58, p = 0.0019). Although highly overexpressed in both groups, 
the levels of SPARC showed trends of being more overexpressed in the PCa group in the PHA fraction and at the 
global protein level (not significant), and merits further study as a potential biomarker in a larger cohort with 
greater statistical power.
Despite very similar patterns of protein and glycoprotein expression, a number of notable statistically signif-
icant alterations were observed between the two groups that should be highlighted. On the global protein level, 
there were five proteins that yielded large positive differences between PCa and BPH means (i.e. the mean PCa 
was greater than that of BPH), were elevated at least 1.5-fold with respect to the reference sample in the PCa group 
(log2H/L ≥ 0.585), and were significantly different between PCa and BPH (p ≤ 0.05). These five proteins were 
CFP, BST1, CD5L, C8A, and C7. CD5L levels were increased 1.5-fold in every M-LAC fraction in PCa group and 
remained relatively unchanged in the BPH group, and yielded one of the most statistically significant differences 
in the dataset (p = 1.52E-07). Additionally, the increase in global levels of proteins AZGP1, and PROS1 were 
significantly different between PCa and BPH (p = 0.0003 and p = 2.33E-06, respectively), however it should be 
noted that AZGP1 and PROS1 were not particularly over-expressed in PCa with respect to the reference sample 
(both yielded log2H/L values around 0.35, or a 1.25-fold increase), making these proteins less ideal as potential 
candidates for diagnostic biomarkers.
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In the above mentioned proteins, separating by glycoform using lectins did not reveal any differences 
in glycosylation pattern, although the additional chromatography step may have aided in detecting these 
moderately-abundant proteins. The real advantage of using an M-LAC approach was made evident when 
glycoform-specific changes in protein levels were observed between PCa and BPH groups, especially when no 
changes were evident at the global protein level. These alterations in glycoform expression would be missed 
without lectin fractionation. The most notable glycoform-specific alterations were observed in the PHA frac-
tion, which contained glycoforms with highly-branched complex type glycans. The degree of branching among 
N-linked glycan structures has been previously shown to be differentially expressed in cancer, with a reported 
increase in the expression of complex N-glycans with a β1,6-branched GlcNAc due to the increased activity 
of acetylglucosaminyltransferase GNT-V13,24. Overexpression of tri- and tetra-antennary N-glycan struc-
tures has been observed in cell line xenograft mouse models of prostate cancer and has been associated with 
castration-resistant prostate cancer in human patients18. Here, we observe some of the most significant differ-
ences in PHA glycoforms in proteins CD163 (p = 0.034), C4A (p = 0.019), and ATRN (p = 0.007), all of which 
were over-expressed in the PCa group. ATRN (attractin) has been reported as an important predictor of Gleason 
score and has been proposed as a diagnostic marker in human sera in a study by Cima et al. in a genetics-guided 
proteomic experiment that looked for differential expression of potential glycoprotein biomarkers that were 
discovered in Pten cKO mice in the sera of men with localized prostate cancer compared to men with BPH56. 
CD163 has also been associated with prostate cancer. Interestingly, CD163 (hemoglobin scavenger receptor 
M130), is a secreted glycoprotein expressed by tumor-associated type M2 macrophages, and has been reported 
to be associated with prostatic inflammation and upregulated in prostate cancer with regard to tumor extension, 
metastasis, and biochemical recurrence57–60. In this study, CD163 was only detected and quantitated in the AAL 
and PHA fractions (no non- or otherwise glycosylated forms), suggesting the presence of core-fucosylation and 
extensive branching of complex type glycans. Furthermore, CD163 was significantly increased in the PHA frac-
tion of PCa samples compared to BPH, but was only slightly over-expressed compared to the reference sample 
(PCA log2H/L = 0.373, BPH log2H/L = −0.610, p = 0.034). The CD163 glycoforms in the AAL fraction were 
also slightly elevated with respect to the reference sample, but were not statistically different from the BPH glyco-
forms. Given these data, CD163 glycosylation patterns and overexpression merit further investigation in a larger 
cohort. It should be noted that although AAL and PHA-L/E lectins are widely used, and their specificity is well 
documented, the exact glycan structure are not elucidated using this method, and additional glycomic or intact 
glycopeptide experiments would need to be performed to confirm glycan composition14. We have previously 
published a study that profiled intact glycopeptides derived from plasma glycoproteins, and have confirmed the 
presence of fucosylated glycopeptides were identified for CD163, C4A, and ATRN, and highly branched glyco-
peptides were identified for C4BPB and AZGP161 in plasma.
Significantly increased expression among core-fucosylated glycoforms was not commonly observed. Most 
statistically significant difference found in this M-LAC fraction were observed among proteins that were also 
elevated across all (or most) of the M-LAC fractions, and not to the AAL-bound glycoforms specifically, as shown 
in the proteins of Group A and D in Fig. 4. Notably, PHA and AAL glycoforms of the protein C4BPB were both 
elevated relative to the reference sample and were significantly higher in the PCa group than in the BPH group 
(PHA p = 0.006, AAL p = 0.032), but showed considerable overlap in the log2H/L ratios in the UNB fraction, sug-
gesting increased expression only among these glycoforms. A similar expression pattern was observed in AZGP1.
Although overexpressed proteins arguably make for more definitive measurements in diagnostic biomarkers, 
this study revealed several proteins that demonstrated decreased expression in the PCa group but striking eleva-
tion in the BPH group. Notable among these was the proteoglycan SRGN. SRGN was the most significantly differ-
ent protein in the UNB fraction, with a three-fold increase in the BPH group relative to the reference sample and 
a decrease equivalent in magnitude in the PCa group (PCA log2H/L = −1.53, BPH log2H/L = 1.59, p = 0.003). 
SRGN, or serglycin, has eight o-linked sites carrying glycosaminoglycans and no N-linked glycosylation sites 
(SRGN was identified exclusively in the UNB fraction). Serglycin has been described as being at the crossroads 
of inflammation and malignancy, playing a vital role in immune response through interactions with chemokines, 
cytokines and growth factors62. Interestingly, SRGN was only overexpressed in the BPH group in this study, and 
markedly decreased in the PCa group, suggesting it may be useful in positively identifying cases of inflammation 
associated with BPH.
In summary, we successfully quantitated hundreds of glycoproteins from PCa and BPH patients to inter-
rogate any differential expression between these two groups. Our approach combined traditional bottom-up 
proteomics with a series of chromatographic separations to improve the depth of analysis and to systematically 
screen a complex mixture of proteins for global changes in specific types of glycosylation. Using a multi-lectin 
approach, our method proved to be useful in separating and quantitating specific protein glycoforms, and yielded 
an information-rich dataset. By isotopically labeling cysteine-containing proteins, we were able to determine 
differences in protein expression between the PCa and BPH groups relative to a normal reference sample. Global 
patterns of differential expression of core-fucosylated or highly-branched glycoforms across the quantitated 
fraction of the serum proteome were not consistently observed as they have been previously described in gly-
comic studies that remove the glycan from the protein. In keeping the glycan conjugated to the protein and thus 
retaining protein-specific information, the breadth of the analysis is subject to the dynamic range and sampling 
issues associated with mass spectrometry-based proteomics. Upon removing glycans, the differential expression 
of specific glycan types are cumulative and more readily observed. In this study, we identified alterations among 
the AAL and PHA glycoforms that were localized to specific, individual proteins rather than observing any larger 
systemic difference in glycosylation. The expression of core-fucosylation and highly-branched glycoforms was 
increased in some proteins and decreased in others, with no discernable trend to differentiate the PCa and BPH 
groups. Among considerably similar proteomic and glycoproteomic signatures, a number of proteins showed 
significant differences irrespective of glycosylation, including CD5L, CFP, C8A, C7, and BST1. Additionally, 
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statistically significant glycoform-specific alterations were observed among M-LAC fractions, including SPARC 
in the UNB fraction, CD163, C4A and ATRN in the PHA fraction, and C4BPB and AZGP1 in both the AAL and 
PHA fractions. These alterations in protein expression and differential glycosylation patterns may warrant further 
study in a larger cohort to investigate the reproducibility of our findings, however, a clinically useful biomarker 
would ideally yield a more dramatic fold-change between PCa and BPH than was observed in any proteins in 
this study. A strategy for future validation of any glycoproteins of interest may include the use of antibody-lectin 
assays built to target specific protein glycoforms, such as those use by Sinha, J. et al.63. Additionally, further exper-
iments for analysis of intact glycopeptides may also provide more detailed annotation of protein glycosylation 
status and reveal more specific alterations in glycan structure between PCa and BPH, as lectins, although useful 
tools for separation, provide limited information regarding glycan structure.
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